{"id":"NCT01739595","sponsor":"Repros Therapeutics Inc.","briefTitle":"Phase III Study to Evaluate Morning Testosterone Normalization in Overweight Men With Secondary Hypogonadism","officialTitle":"A Randomized, Double Blind, Placebo Controlled Multi-Center Phase III Study to Evaluate Normalization of Morning Testosterone Levels in Overweight Men With Acquired Hypogonadotropic Hypogonadism and Normal Sperm Concentration","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2012-11","primaryCompletion":"2013-09","completion":"2013-09","firstPosted":"2012-12-03","resultsPosted":"2015-05-27","lastUpdate":"2015-05-27"},"enrollment":181,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Secondary Hypogonadism"],"interventions":[{"type":"DRUG","name":"enclomiphene citrate","otherNames":["Androxal"]},{"type":"DRUG","name":"Placebo","otherNames":["Dummy"]}],"arms":[{"label":"Androxal 12.5 mg","type":"EXPERIMENTAL"},{"label":"Androxal 25 mg","type":"EXPERIMENTAL"},{"label":"Placebo","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of ZA-302 is to determine the effects of Androxal on morning testosterone and reproductive status in younger overweight men with acquired hypogonadotropic hypogonadism (confirmed morning T\\<300 ng/dL) and normal sperm concentration, compared to changes with placebo. Subjects must not have previously been treated with testosterone products within the last 6 months.","primaryOutcome":{"measure":"Subjects With Testosterone in Normal Range After Treatment","timeFrame":"3 months","effectByArm":[{"arm":"Androxal Subjects Pooled","deltaMin":81.3,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"MALE","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":13,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":1,"n":112},"commonTop":["Nausea","Headache","URI","Fatigue","Vomiting"]}}